In T-ALL, alterations to MYB constitute 19% of pediatric/adolescent young adult patients, most commonly presenting as amplification (57%), mutation (22%), and rearrangement (19%) [15]. The gene discussed is MYB; the disease is acute lymphoblastic leukemia.